A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

ClinicalTrials.gov ID: NCT06244771

Public ClinicalTrials.gov record NCT06244771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 Monotherapy and in Combination With Pembrolizumab in Participants With KRAS G12C Mutated Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Study identification

NCT ID: NCT06244771
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Frontier Medicines Corporation; Industry
Enrollment: 293 participants

Conditions and interventions

Conditions

Interventions

FMC-376 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 12, 2024 (Actual)
Primary completion: Oct 2027 (Estimated)
Completion: Apr 2028 (Estimated)
Last update posted: Oct 19, 2026

2024 – 2028

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center	La Jolla	California	92037	Recruiting
University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center	Orange	California	92868	Completed
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Recruiting
Florida Cancer Specialists and Research Institute	Lake Mary	Florida	32746	Completed
Northwest Cancer Centers	Dyer	Indiana	46311	Recruiting
The University of Kansas Cancer Center	Fairway	Kansas	66205	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Community Clinical Trials	Kingwood	Texas	77339	Completed
South Texas Accelerated Research Therapeutics, LLC	San Antonio	Texas	78229	Recruiting
UT Health San Antonio	San Antonio	Texas	78229	Recruiting
START Mountain Region	West Valley City	Utah	84119	Completed
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06244771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 19, 2026 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06244771 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →